AKT1 and cancer: These, in turn, can reactivate dormant DTC proliferation, renew CD133+ cancer cells and endocrine resistance by IL-6/Notch signaling [238] through the IL-6 receptor gp130/gp80 and activated STAT3 [239,240], through VEGF [241] via PI3K/Akt signaling [242], SMAD2 and 3 [121], and the EGFR and ERK pathways [243].